Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Andes virus DNA vaccine
- Development stage
- Phase 1
- Lead developer
- National Institutes of Health
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular (needle-free Jet Injection)
01
Overview
The Andes virus DNA vaccine is an investigational DNA-based vaccine designed to prevent hantavirus pulmonary syndrome (HPS) caused by the Andes virus (ANDV), a rodent-borne hantavirus endemic to South America. The vaccine consists of a plasmid encoding the envelope glycoprotein genes (Gn and Gc) of the Andes virus, delivered via needle-free jet injection. Its mechanism involves inducing host cells to express viral antigens, thereby eliciting neutralizing antibody responses against ANDV. In a Phase 1 clinical trial, the vaccine demonstrated safety and robust immunogenicity in healthy adults, with high seroconversion rates and durable neutralizing antibody titers[5][4][1]. There are currently no FDA-approved vaccines for HPS or ANDV infection.
- Other names
- ANDV DNA vaccine
02
Targets
GC (Vitamin D-binding protein)Gn (Hantaan virus glycoprotein Gn)
Beyond the preview
Go deeper on Andes virus DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Andes virus DNA vaccine.